...
NVAXSMALL

Novavax, Inc.

HealthcareBiotechnology
$10.14
$0.01(-9.38%)
52W$5.01
$11.97
FinancialsValuationvs BNTX
Updated Feb 28, 12:00 AM
RSI75
RS Rating87/99
Beta1.25
Volatility76%
F-Score5/9
Mkt Cap$1.7B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Novavax, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 87), indicating clear outperformance against the broad market. Earnings growth of 159% provides fundamental context to the price action. However, price is extended 22% above the 50-day line, increasing the risk of a mean reversion.

Relative Strength
87
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.25
vs S&P 500
ABOVE MKT
52W Position
74%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$8.31
50 SMA > 100 SMA$7.93
100 SMA > 150 SMA$8.01
150 SMA > 200 SMA$7.75

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$8.97+13.07%ABOVE
50 SMA$8.31+21.96%ABOVE
100 SMA$7.93+27.87%ABOVE
150 SMA$8.01+26.57%ABOVE
200 SMA$7.75+30.84%ABOVE

Price Performance

1D-9.4%
1W+8.3%
1M+9.9%
3M+43.8%
6M+33.8%
YTD+42.2%
1Y+21.7%
3Y+3.1%
52-Week Trading Range74% from low
$10.14
52W Low$5.01
52W High$11.97

Technical Indicators

RSI (14)OVERBOUGHT
74.8
305070
VCP ScoreCOOL
3/10
Base depth: 54.6%

Risk Profile

Beta
1.25
52W Vol
76%
ATR
$0.74
Max DD (1Y)
-36%

Volume Analysis

Today
10
50D Avg
4.21M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25+379%
$2.93
Q2'25-39%
$0.60
Q3'25-64%
$-1.25
Q4'25+159%
$0.30
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+40.97%
5 Years:+118.83%
3 Years:-11.10%
TTM:+64.69%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+293.99%

Stock Price CAGR

10 Years:-19.36%
5 Years:-46.90%
3 Years:+3.07%
1 Year:+21.73%

Return on Equity

10Y Avg:-550.1%
5Y Avg:-1265.7%
3Y Avg:—
Last Year:—

Key Metrics

Market Cap$1.7B
Gross Margin93.5%
Net Margin39.2%
Piotroski F-Score5/9

More NVAX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

NVAX vs BNTXBNTXMRNASMMTPCVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 87 meansNVAX outperformed 87% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.25 means 25% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is NVAX in an uptrend right now?

NVAX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is NVAX overbought or oversold?

NVAX's RSI (14) is 75. The stock is in overbought territory (RSI > 70), which may signal a pullback.

Is NVAX outperforming the market?

NVAX has a Relative Strength (RS) Rating of 87 out of 99. Yes, NVAX is a market leader, outperforming 87% of all stocks over the past 12 months.

Where is NVAX in its 52-week range?

NVAX is trading at $10.14, which is 85% of its 52-week high ($11.97) and 74% above its 52-week low ($5.01).

How volatile is NVAX?

NVAX has a Beta of 1.25 and 52-week volatility of 76%. It's more volatile than the S&P 500 - expect bigger swings.